Equities

Ocean Biomedical Inc

Ocean Biomedical Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.7399
  • Today's Change-0.020 / -2.64%
  • Shares traded63.14k
  • 1 Year change-54.04%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ocean Biomedical, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The Company helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). It offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.

  • Revenue in USD (TTM)0.00
  • Net income in USD-98.59m
  • Incorporated2021
  • Employees9.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Athira Pharma Inc0.00-109.22m24.85m65.00--0.4342-----2.85-2.850.001.490.00----0.00-80.62-30.73-101.80-32.46------------0.00-------23.04------
Mira Pharmaceuticals Inc0.00-12.78m25.28m3.00--11.39-----0.8562-0.85620.000.15010.00----0.00-373.77---737.47-------------3.170.00-------69.77------
Cell Source Inc0.00-6.45m25.67m-----------0.1627-0.16270.00-0.4130.00-------1,300.91-1,758.85---------------5.14---------3.55------
Neurosense Therapeutics Ltd0.00-7.51m25.70m16.00---------0.4392-0.43920.00-0.09430.00----0.00-154.72---470.03----------------------18.10------
Ocean Biomedical Inc0.00-98.59m26.33m9.00---------3.01-3.010.00-2.21---------------------------0.2443--------72.16------
Equillium Inc42.62m-8.32m26.59m45.00--1.19--0.6238-0.2377-0.23771.200.63330.8388--8.85968,704.60-16.37-46.81-29.58-57.36-----19.52-328.35----0.00--128.97--78.64--7.48--
Geovax Labs Inc300.68k-26.92m26.77m17.00------89.02-13.05-13.050.1389-0.55260.0237----17,687.06-212.40-108.34-362.39-147.24-----8,951.51-1,842.93---------100.00---85.20------
GlycoMimetics Inc10.00k-39.11m26.93m35.00--1.34--2,692.85-0.6071-0.60710.00020.31110.0002--0.0685285.71-90.71-43.60-103.87-47.82-----391,132.40-2,243.52----0.00---86.67--20.97---29.82--
Estrella Immunopharma Inc0.00-7.31m27.56m----6.47-----0.1977-0.19770.000.11780.00-------195.43------------------0.00------34.21------
ImmuCell Corp23.22m-4.05m27.65m74.00--1.18--1.19-0.521-0.5212.992.990.54092.3213.47293,961.10-9.43-5.16-10.50-5.5326.0540.04-17.44-12.640.7668-7.430.3243---5.909.72-131.56---1.39--
Tempest Therapeutics Inc0.00-31.75m27.73m17.00--1.59-----1.64-1.640.000.69210.00----0.00-87.09-57.10-127.72-71.20-----------368.160.3861------17.41--36.40--
RenovoRx Inc0.00-8.11m27.82m8.00--3.00-----0.6059-0.60590.000.38680.00----0.00-88.58---106.00--------------0.00-------3.47------
Akari Therapeutics PLC (ADR)0.00-20.13m27.93m9.00---------2.98-2.980.00-0.30490.00----0.00-307.64-149.95---435.18-----------378.19--------43.61------
Data as of Nov 12 2024. Currency figures normalised to Ocean Biomedical Inc's reporting currency: US Dollar USD

Institutional shareholders

10.86%Per cent of shares held by top holders
HolderShares% Held
Polar Asset Management Partners, Inc.as of 30 Jun 20242.69m7.76%
The Vanguard Group, Inc.as of 30 Jun 2024399.88k1.15%
Millennium Management LLCas of 30 Jun 2024168.13k0.49%
Geode Capital Management LLCas of 30 Jun 2024142.90k0.41%
BlackRock Fund Advisorsas of 30 Jun 202494.26k0.27%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 202478.21k0.23%
Goldman Sachs & Co. LLC (Private Banking)as of 30 Jun 202464.99k0.19%
Verition Fund Management LLCas of 30 Jun 202458.16k0.17%
Jane Street Capital LLCas of 30 Jun 202434.64k0.10%
SSgA Funds Management, Inc.as of 30 Jun 202432.80k0.10%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.